Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 381, Issue 9880, Pages (May 2013)

Similar presentations


Presentation on theme: "Volume 381, Issue 9880, Pages (May 2013)"— Presentation transcript:

1 Volume 381, Issue 9880, Pages 1827-1834 (May 2013)
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data  Prof Jack Cuzick, PhD, Ivana Sestak, PhD, Bernardo Bonanni, MD, Joseph P Costantino, DrPH, Steve Cummings, MD, Prof Andrea DeCensi, MD, Prof Mitch Dowsett, PhD, Prof John F Forbes, MD, Leslie Ford, MD, Prof Andrea Z LaCroix, PhD, John Mershon, MD, Bruce H Mitlak, MD, Prof Trevor Powles, MD, Prof Umberto Veronesi, MD, Prof Victor Vogel, MD, D Lawrence Wickerham, MD  The Lancet  Volume 381, Issue 9880, Pages (May 2013) DOI: /S (13) Copyright © 2013 Elsevier Ltd Terms and Conditions

2 Figure 1 Cumulative incidence for all breast cancer (including ductal carcinoma in situ) and all ER-positive invasive cancers in years 0–10 according to treatment allocation SERM=selective oestrogen receptor modulator. ER=oestrogen receptor. The Lancet  , DOI: ( /S (13) ) Copyright © 2013 Elsevier Ltd Terms and Conditions

3 Figure 2 Annual hazard rate for all breast cancers (including ductal carcinoma in situ) and invasive ER-positive breast cancer in years 0–10 with fixed-effects models23 ER=oestrogen receptor. SERM=selective oestrogen receptor modulator. The Lancet  , DOI: ( /S (13) ) Copyright © 2013 Elsevier Ltd Terms and Conditions

4 Figure 3 All breast cancers, invasive breast cancer, and DCIS in years 0–10 ER=oestrogen receptor. DCIS=ductal carcinoma in situ. *Adjusted by overall tamoxifen effect to give raloxifene versus placebo comparisons. † STAR data not included in comparisons. ‡Data for ER-invasive cancer are pooled. The Lancet  , DOI: ( /S (13) ) Copyright © 2013 Elsevier Ltd Terms and Conditions

5 Figure 4 Forest plots for adverse events
(A) Endometrial cancer, other cancer, venous thromboembolic events, and cardiac or stroke events. (B) All fractures, vertebral fractures and non-vertebral fractures. *Adjusted by overall tamoxifen effect to give raloxifene versus placebo comparisons. † STAR data not included in comparisons. ‡Data are pooled. The Lancet  , DOI: ( /S (13) ) Copyright © 2013 Elsevier Ltd Terms and Conditions


Download ppt "Volume 381, Issue 9880, Pages (May 2013)"

Similar presentations


Ads by Google